Fingerprint
Dive into the research topics of 'Disability progression after switching from natalizumab to fingolimod or interferon beta/glatiramer acetate therapies: A NARCOMS analysis'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically